Seeking Alpha

After trading lower premarket on an extended FDA review for its Tysabri drug, Biogen Idec (BIIB)...

After trading lower premarket on an extended FDA review for its Tysabri drug, Biogen Idec (BIIB) is up 5.3%, as investors choose to focus on positive trial data for the company's BG-12 drug for treating MS. Jefferies says it now has "increased confidence" BG-12 will be the leading front-line treatment for MS."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|